Research programme: mitochondrial disease therapeutics - Chondrial Therapeutics

Drug Profile

Research programme: mitochondrial disease therapeutics - Chondrial Therapeutics

Alternative Names: CTI-1601

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indiana University; Wake Forest University School of Medicine
  • Developer Chondrial Therapeutics
  • Class Proteins
  • Mechanism of Action Frataxin protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Friedreich's ataxia

Most Recent Events

  • 03 Aug 2017 CTI-1601 receives Orphan Drug status for Friedreich's ataxia in USA
  • 08 Feb 2017 Chondrial Therapeutics in-licenses technology from Indiana University Research and Technology Corporation and Wake Forest University Health Sciences
  • 06 Feb 2017 Chondrial Therapeutics announces intention to submit NDA to the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top